glenmark pharmaceuticals (Citi) IFRS Skews FY11 Numbers; No Major Surprises

Adj PAT Inline; Guidance Mixed; IFRS skews FY11 financials; Revenue growth remains strong; Adj PAT growth strong, EBITDA margin lower
Date Rating Target Price Recommendation Price Broker house
11 May 2011 buy 360 284 Citi Report

No comments:

Post a Comment